INVO Fertility Receives Nasdaq Notification Regarding Late Filing of Quarterly Report on Form 10-Q
Rhea-AI Summary
INVO Fertility (Nasdaq: IVF) received a Nasdaq delinquency notice on May 27, 2026 for not timely filing its 2025 Form 10-K and Q1 2026 Form 10-Q with the SEC.
The 10-K was filed on June 2, 2026, and the company is working to complete the 10-Q. Nasdaq has set compliance plan and potential extension deadlines, while IVF shares continue trading.
Positive
- Filed delayed 2025 Form 10-K with the SEC on June 2, 2026
- Completed $7.5 million financing in January 2026 to support operations
- Acquired Family Beginnings fertility clinic in Indiana to expand operations
- Potential Nasdaq extension of up to 180 days to regain filing compliance
Negative
- Currently non-compliant with Nasdaq Listing Rule 5250(c)(1) due to late SEC filings
- Must submit a Nasdaq compliance plan by June 22, 2026
- Risk of Nasdaq Hearings Panel process if compliance plan is not accepted
News Market Reaction – IVF
In the Jun 3 session, IVF gained 11.84%, reflecting a significant positive market reaction. Argus tracked a peak move of +35.0% during that session. Our momentum scanner triggered 20 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 29 | Nasdaq delinquency notice | Negative | -2.1% | Nasdaq notice for late Form 10-K filing and compliance timeline. |
| Mar 25 | Reverse stock split | Negative | -6.2% | Announcement of 1-for-5 reverse stock split and share adjustments. |
| Mar 05 | Clinic technology upgrade | Positive | -2.1% | Adoption of time-lapse embryo incubation tech at Wisconsin clinic. |
| Mar 03 | Network expansion | Positive | -7.0% | Wisconsin clinic joining Progyny network to expand payor access. |
| Feb 19 | Clinic acquisition | Positive | -4.2% | Closing of Family Beginnings acquisition to add a Midwest clinic. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent company updates, even operationally positive ones, have often been followed by negative price moves, while compliance and capital-structure headlines have also aligned with downside reactions.
Over the last few months, IVF has reported several material developments: Nasdaq delinquency notices on its Form 10-K, a 1-for-5 reverse split, technology upgrades at its Wisconsin clinic, the clinic’s entry into the Progyny network, and the acquisition of Family Beginnings for $760,000. Despite some growth-oriented announcements, each event was followed by a negative 24-hour move, framing today’s additional Nasdaq delinquency notice within an already pressured trading backdrop.
Key Terms
nasdaq listing rule 5250(c)(1) regulatory
form 10-k regulatory
form 10-q regulatory
variable interest entities financial
derivative accounting financial
nasdaq hearings panel regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
SARASOTA, Fla., June 02, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO” or the “Company”), a healthcare services fertility company, today announced that on May 27, 2026, it received a delinquency notice (the "Notice") from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the "SEC"). The Notice relates to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the "10-K"), and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 (the "10-Q").
The Notice has no immediate effect on the listing of the Company's common stock on Nasdaq, and the Company's common stock will continue to trade on Nasdaq under the symbol “IVF” at this time.
The Company filed the 10-K with the SEC on June 2, 2026, and is working diligently to complete and file the 10-Q as soon as possible. The previous delay in filing the 10-K was due to additional time required to review certain complex accounting matters, including its tax provision, variable interest entities, and derivative accounting.
The Company expects the pending first quarter 10-Q to reflect further progress on its core business objectives, which included the completion of a
Pursuant to Nasdaq Listing Rule 5810(c)(2)(F), the Company has 60 calendar days from Nasdaq's April 23, 2026 notice regarding the 10-K delinquency to submit a compliance plan, which is no later than June 22, 2026. If Nasdaq accepts the plan, the Company may be granted up to 180 calendar days from the 10-K’s due date, or until October 13, 2026, to regain compliance. If Nasdaq does not accept the plan, the Company may appeal to a Nasdaq Hearings Panel.
This press release is being issued pursuant to Nasdaq Listing Rule 5810(b), which requires prompt public disclosure of receipt of a deficiency notice.
About INVO Fertility
We are a healthcare services fertility company dedicated to expanding access to assisted reproductive technology (“ART”) care to patients in need. Our principal commercial strategy is focused on building, acquiring, and operating fertility clinics, including “INVO Centers” dedicated primarily to offering the intravaginal culture (“IVC”) procedure enabled by our INVOcell® medical device (“INVOcell”) and US-based, profitable in vitro fertilization (“IVF”) clinics. We have four operational fertility clinics in the United States. We also continue to engage in the sale and distribution of INVOcell to third-party owned and operated fertility clinics. INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman's body. The IVC procedure provides patients with a more connected, intimate, and affordable experience in comparison to other ART treatments. We believe the IVC procedure can deliver comparable results at a fraction of the cost of traditional IVF and is a significantly more effective treatment than intrauterine insemination. For more information, please visit invofertility.com.
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties, and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.
For more information, please contact:
INVO Fertility, Inc.
Steve Shum, CEO
978-878-9505
sshum@invofertility.com
Investor Contact
Lytham Partners, LLC
Robert Blum
602-889-9700
INVO@lythampartners.com
